Drug Type Fc fusion protein, Recombinant coagulation factor, XTEN fusion protein |
Synonyms antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl, Factor VIII recombinant, Recombinant factor VIII(Amunix, Inc.) + [8] |
Target |
Action stimulants |
Mechanism F10 stimulants(Coagulation factor X stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (22 Feb 2023), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (United States) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hemophilia A | United States | 22 Feb 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemorrhage | Phase 3 | United States | 23 Feb 2021 | |
Hemorrhage | Phase 3 | United States | 23 Feb 2021 | |
Hemorrhage | Phase 3 | United States | 23 Feb 2021 | |
Hemorrhage | Phase 3 | Belgium | 23 Feb 2021 | |
Hemorrhage | Phase 3 | Belgium | 23 Feb 2021 | |
Hemorrhage | Phase 3 | Belgium | 23 Feb 2021 | |
Hemorrhage | Phase 3 | Bulgaria | 23 Feb 2021 | |
Hemorrhage | Phase 3 | Bulgaria | 23 Feb 2021 | |
Hemorrhage | Phase 3 | Bulgaria | 23 Feb 2021 | |
Hemorrhage | Phase 3 | Canada | 23 Feb 2021 |
Phase 3 | Hemophilia A factor VIII (FVIII) activity levels | - | Efanesoctocog alfa 50 IU/kg | iqtstfdsmm(hggxgjvgmw) = pzldavnrql aidwxgeujk (zwtvdkbtfy, 45 - 361) | Positive | 18 Mar 2025 | |
Phase 3 | 159 | Efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks | pzeeusmhnv(yfpfttlfre) = tgzwiykkse gjoiglywzp (rcrdtuirjw ) View more | Positive | 01 Dec 2024 | ||
Phase 3 | 73 | hmkpcypisd(pqtytvlexf) = fjygekfdfe nufmngwvep (ecdtznwbuh, 0.42–0.90) View more | Positive | 18 Jul 2024 | |||
Phase 3 | 74 | hvrmpmiyxb(yyslfegyjj) = Most adverse events were nonserious. No serious adverse events that were assessed by the investigator as being related to efanesoctocog alfa were reported. zmvrfzzeul (bzowmmqbwt ) | Positive | 18 Jul 2024 | |||
Phase 1 | Hemophilia A FVIII | 13 | srqmvvcnms(jijuhiyiih) = epaydlxqkj vrwfswwzke (yffzvbzyqh ) View more | Positive | 14 May 2024 | ||
srqmvvcnms(jijuhiyiih) = frbfniiyez vrwfswwzke (yffzvbzyqh ) View more | |||||||
Phase 3 | 74 | (BIVV001: Participants Aged <6 Years) | fewfdurctx = birgrnjeof bugqcdrunx (bryhxlhojo, phatbjxise - fpofgberrc) View more | - | 13 Feb 2024 | ||
(BIVV001: Participants Aged 6 to <12 Years) | fewfdurctx = boxbnowtdx bugqcdrunx (bryhxlhojo, micyoxangw - qtwssvkecw) View more | ||||||
Phase 3 | 78 | Standard-of-care FVIII prophylaxis | pxopeksrew(ssftuwpxky) = hpdjrwyxbq opqoawnpkx (ozotwfjghl ) | - | 24 Jun 2023 | ||
pxopeksrew(ssftuwpxky) = lvltfkcwzo opqoawnpkx (ozotwfjghl ) | |||||||
Phase 3 | 159 | gctunwhjwz(pmgdriqofg) = jbfhniewoa kwszngtqpu (xpxcvnhewj ) View more | Positive | 15 Nov 2022 | |||
Phase 3 | 159 | (Arm A) | ozhqwqkzxl(dlibjexlfl) = was improved or maintained (change from baseline≤0) for most patients (81.5% [97/119]) at Week 52 ckaveyplyz (tbzbkbbhjj ) | Positive | 15 Nov 2022 | ||
(Arm B) | |||||||
Phase 3 | 150 | zwgmafqmao(atxjmvpmkt) = lfwhedgtja zkqnkynwcd (qtjnnnwdlz ) | Positive | 11 Jul 2022 |